
    
      At entry to the research protocol the up-till then administered treatment with Intra Venous
      FOLFIRI+BEVACIZUMAB will be stopped.Instead, the research oral treatment will be initiated to
      be taken daily on an ambulatory basis and under once monthly re-evaluation. If and when
      disease progresses the original FOLFIRI+BEVACIZUMAB treatment will be considered for
      re-institution.
    
  